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Background: The CFTR gene is tightly regulated and differentially expressed in many mucosal epithelial cell types. There is evidence of an
increasing number of genomic variations in the intronic regions influencing mRNA splicing, and also the level of normal CFTR transcript.
Methods: In the present study, we investigate the molecular defect by RT-PCR analyzing the mRNA of 25 cystic fibrosis (CF) patients in whom
only one or no CF allele had been identified after DNA analysis (of all the exons of the CFTR gene).
Results: mRNA analysis led to the detection of a cryptic exon in two patients: the new exon is a 104 bp insertion between exons 10 and 11 and is
caused by a new point mutation c.1584+18672 bp ANG (http://www.hgvs.org/mutnomen/) discovered in intron 10; moreover, they showed the
absence of exon 9 skipping.
Conclusions: Our results confirm the utility of RNA analysis in discovering new mutations and in investigating their effect on normal splicing
processes.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Splicing; CFTR; mRNA; Cystic fibrosis; Pseudo-exon1. Introduction
Cystic fibrosis (CF; MIM# 219700) is the most frequent
severe autosomic recessive disorder in the European population,
affecting approximately 1/2500 births [1]. The disease affects
the epithelial cells of several organs, resulting in a variable
clinical picture characterized by suppurative lung disease,
pancreatic insufficiency, biliary cirrhosis, male infertility and
high sweat electrolyte loss. To date, more than 1600 mutations
have been reported (http://www.genet.sickkids.on.ca/cftr) with
only a minority being characterized at the RNA level. About
13% of CFTR mutations are classified as “splicing mutations”,
but for most of them, their role in affecting pre-mRNA⁎ Corresponding author. Tel.: +39 02 55032432; fax: +39 02 55032277.
E-mail address: laboratorio.genetica@policlinico.mi.it (M. Seia).
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doi:10.1016/j.jcf.2010.08.009splicing of the gene has not yet been completely defined [2].
The most common mechanism that has been described implies
that mutations can act by directly disrupting or creating a
splice site [3], and inducing the formation of abnormal mRNA
populations.
Splicing is an essential intra-nuclear process occurring in
eukaryotic cells, allowing the removal of non-coding sequences
from pre-mRNA and the generation of mature mRNA. Pre-
mRNA may undergo classical splicing (thus generating a single
variety of mRNA and hence a single protein), or alternative
splicing, which in contrast, generates more than one combina-
tion of coding sequence and hence a variety of mRNAs/proteins.
Alternative splicing, therefore, plays a central role in the
regulation of cellular gene expression and homeostasis [4].
It has also been suggested that RNA secondary structures
play a significant role in helping the splicing machinery
distinguish between real exons and pseudo-exon sequences [5].d by Elsevier B.V. All rights reserved.
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sequences between 50 and 200 nt in length and flanked by
apparently good-to-consensus acceptor and donor-site signals
[4,6]. This reduced length, intriguingly similar to the true exon
and available for folding after transcription [7], suggests that the
intrinsic structural features of these RNA sequences could
potentially represent a major determinant in their ‘exonization’
process, and also potentially determine their recognition by the
splicing machinery.
Pseudo-exon inclusion events have increasingly been
described as a result of a single-point mutation which occurs
deep within the intronic region in patients with CF [8,9]. In
general, these mutations have the effect of creating either a very
good acceptor or a donor splice site, followed by the selection of
“opportunistic” complementary sites [4,10]. Although the
production of a new exon, by creating a new splice site, has
been reported for the CFTR gene [11] and for several other
genes [12], it still remains an infrequent phenomenon as it
requires other splice determinants to be in the correct position in
order to become active.
We report the identification and characterization of a new
mutation, c.1584+18672 bp ANG, found in two CF patients;
the mutation occurs in intron 10 of the CFTR gene and causes
the appearance of a new donor splice site inducing a pseudo-
exon formation in the CFTR mRNA molecule.2. Patients and methods
2.1. Patients
We selected 25 CF patients (with a classic form of CF), out
of a total of 800 followed at the CF centre of Milan, whose
genotype could not be determined after extensive analysis at
the DNA level. Informed consent was collected from patients.
Analysis also included 7 normal control subjects to find out
whether there were abnormal CFTR mRNA populations in
epithelial cells.2.2. DNA analysis
In all 800 subjects, DNA was extracted from blood, using a
semi-automated extractor (Quick-Gene-810 Fujifilm, Tokyo,
Japan), according to the manufacturer's instructions. The first
level of screening of the most frequent mutations was
performed using a commercial kit (Inno-Lipa CFTR19, Inno-
LipaCFTR171TnUpdate, Inno-Lipa CFTR-ItalianRegional —
Innogenetics, Ghent, Belgium). Moreover, the unidentified CF
alleles were extensively analyzed by sequencing. In order to
detect rearrangements in the CFTR gene, the 27 exons were
screened in patients with uncharacterized mutations, using the
MLPA assay based on a commercial kit, SALSA P091 CFTR
MLPA, according to the manufacturer's instruction (MRC
Holland, Amsterdam, Holland).
Mutation names were those reported according to the HSVG
nomenclature (http://www.hgvs.org/mutnomen/).2.3. RNA analysis
Cells were collected from the nasal epithelium of 25 patients
not completely characterized after DNA analysis, by gently
brushing the inferior turbinates of both nostrils [13] using a
cyto-brush (REF EBR1 S01 Biogyn Italy).
RNA was extracted by a guanidinium isothiocyanate/phenol
method (RNAZOL, Invitrogen Life Technologies, Groningen,
Netherlands) and then subjected to digestion with RNase-free
DNase I (Promega GmbH,Mannheim, Germany). One μg of the
total RNAwas reverse transcribed using hexanucleotide primers
and high capacity cDNA Archive kit (Applied Biosystems).
cDNA was amplified by PCR in six overlapping fragments
spanning the entire gene using FastStart Taq DNA Polymerase
(Roche) [14]. The PCR thermal cycling conditions were as
follows: initial denaturation at 95 °C for 6 min; 30–36 cycles
at 95 °C for 30 s, annealing at 60 °C for 1 min and extension
at 72 °C for 2 min, followed by a final extension at 72 °C
for 8 min. In particular, we designed a PCR spanning from
exon 9 with primer forward 9 (5′-CGAGCTCCAATTCCAT-
GAGC-3′) to exon 13 with primer reverse B1L1972 [14], to
explore the abnormal pathway. The PCRwas tested by running
5 μl of the product on a 1.5% agarose gel in order to identify
large deletion/insertions and the product of possible alternative
splicings.
The basic local alignment search tool (BLAST) program
was used to identify the corresponding intronic fragment in the
abnormal mRNA.
To amplify intron 10, primers IVS10 forward, located between
nt 98028 and nt 98050 (5′-GCCAAGTTATTGTACAGTT-
GACC-3′), and IVS10 reverse, located between nt 98376
and nt 98354 (5′-TGACCAGAAGCCTTACTGATAAC-3′),
complementary to flanking intronic sequence, were used.
Sequencing reactions of both amplified cDNA and intron 10
were carried out using BigDye Terminator cycle sequencing kit
(Applied Biosystems,). Sequence analyses were performed with
ABI PRISM 3130 (Applied Biosystems).
To evaluate exon 9 skipping, a PCR using primers B1R998
and B1L 1972 was performed [14].2.4. Molecular cloning
The PCR products that presented an aberrant profile were
gel-purified using a QIAquick gel extraction kit (Qiagen
GmbH, Hilden,Germany), sequenced and sub-cloned into the
pCR2.1-TOPO vector (TOPO TA cloning kit, Invitrogen,
San Diego, CA, USA) and then used to transform TOP10
chemically competent E. coli cells (Invitrogen, San Diego, CA,
USA). Transformed cells were grown on Lauria broth-agar
plates containing ampicillin (100 μg/ml), and X-gal (80 μg/ml).
Positive colonies were obtained via blue–white selection.
Plasmid DNA was extracted from the bacteria using the
Wizard® Plus SV Minipreps DNA Purification System
(Promega,). About 50 clones were analyzed for each cloned
fragment, and 2 μl of the plasmid DNA then sequenced using
M13F/M13R primers.
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Quantitative analysis at the mRNA level was performed in
20 μL-reaction volume with TaqMan® assay Fast Universal
PCRMaster Mix, and with TaqMan assay Hs01565544_m1 and
Hs01565545_m1 (Applied Biosystems). In the first assay, the
probe binds in the region of CFTR between exon 7 and 8,
precisely in position 1000; in the second assay, the probe binds
the region between exon 9 and 10, exactly in position 1345. For
this experiment we used 7500 Fast Real-Time PCR System.
Two different probes were used: the first probe detected
the level of total RNA as it binds the region located from exon
7 to 8; the second probe detects the level of mRNA popu-
lations without exon 9, as it binds from the 3′ end of the
region of exon 9 to the 5′ end of the region of exon 10. The
ΔCt=(Cttarget−overage Ctreference) method was used to calcu-
late the quantity of gene expression.
CFTR mRNA expression was normalized using the
housekeeping gene HPRT and was compared to the expression
of wt CFTR (normalized to HPRT).
2.6. In silico tools
The genomic sequence environment of the mutation was
analyzed for 5′ and 3′ splice sites using NNSplice (available at
www.fruitfly.org/seq_tools/splice.html) [15], Spliceview
(http://zeus2.itb.cnr.it/~webgene/wwwspliceview.html) tools
for prediction and analysis of protein-coding gene structure
and the online ESEfinder web interface (http://rulai.cshl.edu/
cgi-bin/tools/ESE3/esefinder.cgi?process=home) [16].
With ESEfinder web interface we analyzed the mutated
sequence using four sequence-motif matrices that predict
functional exonic splicing enhancers (ESEs) recognized by
the serine–arginine rich (SR) proteins SF2/ASF, SC35, SRp40
and SRp55. These matrices are derived from pools of functional
enhancer sequences selected iteratively in vitro [17].
Motif scores reflect the extent of matching to a degenerate
consensus and are adjusted for background nucleotide compo-
sition. Default threshold settings used were 1.956 for SF2/ASF,
2.383 for SC35, 2.670 for SRp40, and 2.676 for SRp55. The
scoring system for ESEfinder ranges from default threshold (no
effect) to positive values, which predict an increasing
probability that a specific mutation is damaging at the molecular
level.
With this model, we also analyzed the effect of mutation
c.1584+18672 bp ANG on splicing elements, such as U2
snRNP, that binds to the branch site and the U1 snRNP particle
that binds to the upstream and downstream 5′ splice sites.
3. Results
The molecular analysis performed at the DNA level on 800
patients was unable to identify the defect in 101 CF alleles; in
particular, in 57 subjects, one allele was unidentified, and in 22
subjects both CF alleles were unknown. In order to characterize
these alleles, we selected 25 patients that were re-collected and
analyzed at the mRNA level. Out of 25 patients, four presentedan insertion of 101 bp between exon 6b and 7 [2], two patients
revealed low expression of the CFTR gene and the remaining
patients are under evaluation. Two unrelated patients, F508del
heterozygous, showed the same abnormal pathway on mRNA
analysis. Both presented a classical clinical form of cystic
fibrosis with pancreatic insufficiency (PI), chronic lung disease
with Pseudomonas aeruginosa infection, and sweat Cl− con-
centration over 60 mmol/l (Cl).
The gel electrophoresis of cDNA PCR fragments, which
span from exon 9 to exon 13, showed two fragments of about
600 bp and 700 bp in both patients, instead of the single 604 bp
fragment identified in control subjects (Fig. 1a).
The extraction from agarose gel and sequencing of this extra
fragment (708 bp) showed a 104 bp insertion between exon 10
and 11 that resembles a cryptic exon (Fig. 1b).
Analysis by Blast software showed that the inserted
sequence is identical to the part of the downstream sequence
of intron 10 between IVS10 nt 98125 and IVS10 nt 98228
(NCBI Reference Sequence: NT_007933.15). To explore the
cause of this insertion in greater detail, IVS10F and IVS10R
primers were used to amplify and sequence the flanking
genomic regions.
Analysis of the upstream CFTR intron 10 region flanking the
104 bp sequence presented an “ag” putative 3′ splice site
(branch site and polypyrimidine tract with 10 pyrimidines long).
Sequence analysis of the downstream region of the 104 bp
sequence identified a new mutation, c.1584+18672 bp ANG.
This mutation creates a “gt” putative cryptic 5′ donor splice site
which was most probably recognized by the spliceosome and
led to the insertion of a 104-nucleotide cryptic exon into the
mRNA molecule.
The mutation is located 5 nt downstream from the 5′ end of
the cryptic exon (Fig. 2). Also analysis by NNsplice prediction
program of normal and variant sequences of intron 10 revealed
the formation of a “gt” putative cryptic 5′ donor splice site
(atgaatagtacgtac) when the mutation c.1584+18672 bp ANG
was present; the NNSplice donor-site score ranged from 0, in the
absence of mutation, to 0.86 when substitution took place.
This value (0.86) indicates a difference in the predicted
strengths in favour of 5′ donor splice site and was confirmed by
another donor-site scoring method, Spliceview, with a normal/
mutated score of 0/75. Using the ESEfinder program, which
evaluates a possible interaction between the genomic sequence
and the 5SS_U2_human [16], we obtained a score ranging from
1.08410 to 3.60090 (Fig. 3b). Furthermore, the genetic profile
was investigated in both parents of the two CF mutated patients;
the c.1584+18672 bp ANG mutation was identified in each of
the two parents who were not carriers of F508del allele. They
also had an mRNA profile reflecting the presence of this new
mutation.
The PCR product spanning exon 10 to exon 13 of both
patients was cloned into the TOPO TA 2.1 plasmid. About 50
positive clones were analyzed for each patient.
Digestion with EcoRI enzyme and subsequent sequencing
analysis revealed that about 70% of positive clones carried the
F508del mutation but did not present the 104 bp insertion
between exon 10 and 11. The other 30% of positive clones had
Fig. 1. RT-PCR analysis of CFTR mRNA from nasal brushing of two patients and two control subjects. After amplification of cDNA, only one band of 604 bp was
obtained from the control subjects n. 1, 4 while an additional band of 708 bp was obtained from CFTR patients n. 2, 3. (a) The 708 bp RT-PCR product was excised
from agarose gel and the sequence determined and cloned in the plasmid vector. Sequencing results reveal an aberrant mRNAwith a 104 bp insertion between exon 10
and 11 that resembles a cryptic exon. (b) The ladder used in this experiment was the 50 bp DNA Ladder, Invitrogen.
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F508del mutation.
To investigate the presence of this mutation in our
population we studied 50 CF patients with two identified
mutations, 45 non CF subjects, and 23 CF patients with oneor two unidentified mutations, at the DNA level. None of
the 118 analyzed subjects carried the c.1584+18672 bp ANG
mutation.
In addition, PCR analysis was performed at the RNA level
in 23 CF patients and 7 controls, to verify exon 9 skipping. As
Fig. 2. The c.1584+18672 bp ANG substitution is indicated by the letter “g”. Boxes containing lined bars represent the 104 bp inserted sequences of intron 10. The
intronic sequence is represented by 5′-a-b-c-d-3′. The mutation creates the putative donor splice site that is underlined.
Fig. 3. The figure shows the results obtained by ESEfinder 3 web interface (Cartegni at al, 2003). We analyzed the new mutation c.1584+18672 bp ANG using four
sequence motifs that predict functional ESEs recognized by the SR proteins (SF2/ASF, SC35, SRp40, SRp55) and the splicing factors (5SS_U2_human,
3SS_U2_human, BranchSite). The mutation occurring in intron 10 generates: a) a new SRp55 motif (from 4.55 to 5.16) and b) a new 5SS_U2_human (from 1.08410
to 3.60090), the other motif score remains unchanged. ⋆Indicates the sequence (atgaatagtacgtac) of putative donor splice site.
415L. Costantino et al. / Journal of Cystic Fibrosis 9 (2010) 411–418
416 L. Costantino et al. / Journal of Cystic Fibrosis 9 (2010) 411–418reported, we found the presence of different levels of exon 9
skipping in CF patients and in normal subjects, while in two
patients carrying the c.1584+18672 bp ANG mutation we
observed the complete absence of exon 9 skipping (Fig. 4).
These results were confirmed by real-time quantification
(data not shown) where, in patients carrying the c.1584+
18672 kbANG mutation, the mRNA fragment with exon 9
skipping was absent. To better analyze the correlation between
the c.1584+18672 bp ANG mutation and exon 9 skipping we
used a computational approach to predict any changes of ESE
motif [16], and we observed that this mutation caused a change
in the putative motif score (SRp55 — normal/mutated score:
4.55/5.16) (Fig. 3a).
4. Discussion
About 6% of CF alleles in our population remain
unidentified, even after extensive studies of the CFTR gene
by PCR-based procedures [18]. At present, mRNA analysis is
not used as a routine procedure to identify CFTR mutation in
medical genetic services. However, we believe that mRNA
analysis represents an effective tool for the identification of
unknown molecular defects of the CFTR gene, with the
potential of improving diagnostic detection rate.
In addition, mRNA analysis may increase overall under-
standing of the pathogenic role of sequence variation and
splicing defect causing alternative products [19].
The present study led to the identification and charac-
terization, in two independent patients, of a new c.1584+
18672 bp ANG mutation, which occurs within intron 10 of
the CFTR gene and causes an insertion of 104 bp between exon
10 and exon 11, at the mRNA level.
The sequence search by Blast database of the 104 bp element
showed that the inserted sequence is identical to the part of the
downstream sequence of intron 10 between IVS10 nt 98125 and
IVS10 nt 98228 of the CFTR gene. This finding can be
explained by the activation of a cryptic splice site by a singular
intron mutation that creates a very good acceptor or donor splice
site followed by the selection of opportunistic complementary
sites.Fig. 4. Agarose gel electrophoresis of amplified cDNA fragment spanning exons 7–1
183 nucleotides of exon 9. Patients 4 and 5 carrying the new mutation c.1584+186
skipping. The ladder used in this experiment was the 50 bp DNA Ladder, InvitrogeNNSplice program analysis revealed that the donor-site
score ranged from 0, in the absence of mutation, to 0.86 when
the substitution took place. Increasing score value indicates a
higher probability of a new splice site creation. In particular, the
c.1584+18672 bp ANG mutation creates a new gt 5′ donor
splice site, which generates the aberrant splicing and determines
the inclusion of the cryptic exon out of the reading frame
predicted to lead to the insertion of 34 amino-acid residues in
the protein followed by a stop codon. The CFTR protein
produced by this anomalous transcript should be truncated soon
after exon 10. The stop signal is located in the nucleotide
binding domain region (NBD) of the protein and can lead to the
formation of a non-functioning protein, or the abnormal
transcript may be degraded before translation through non-
sense-mediated mRNA decay (NMD) [20].
Therefore, since the stop codon in our sequence is located
104 nt downstream of the last exon–exon junction, the NMD
mechanism can affect our population of abnormal mRNA.
Further studies are necessary to verify this hypothesis.
A non-functioning protein could explain the clinical pheno-
type of the two mutated patients. We have also demonstrated, by
cloning experiment, that the wt mRNA of the two patients is not
present.
Multiple factors are known to be involved in the regulation
of alternative splicing through a complex network of interaction
between splicing factors and pre-mRNA elements. Different
splicing factors belonging to the SR protein family and
heterogeneous nuclear ribonucleoprotein (hnRNP) have been
shown to regulate the alternative splicing of many pre-mRNA
[21,22].
Generally, SR proteins are considered to bind ESE
sequences and then promote exon inclusion in the pre-mRNA
molecule, which is subsequently processed by the spliceosoma
[23,24].
It has been recognized that the alternative splicing of CFTR
exon 9 skipping is regulated by the intracellular concentration
of various splicing factors [21]. We hypothesize that the new
mutation may interfere with the spliceosoma machinery
producing the pseudo-exon inclusion and may prevent exon 9
from being skipped by affecting the mRNA structures. In3 PCR, in patients (1–7) and normal controls (8–14). The 730 bp fragment lacks
72 bp ANG presented the extra band and did not reveal the band without exon
n.
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of the band representing the exon 9 skipping in the two patients
carrying this new mutation, which was instead present in all
control patients and normal subjects, as already described in the
literature [25,26].
These data suggest a correlation between the new c.1584+
18672 bp ANG mutation and the absence of the mRNA, with
exon 9 skipping confirmed also by real-time PCR.
To verify this hypothesis, we used a computational approach
to predict any changes in the putative motif score. The analysis
by online ESEfinder database of normal and variant sequences
of intron 10 revealed a changing in the score of SRP55. This
increase in the score value, from 4.55 to 5.16, may influence the
exon 9 skipping rate.
It has previously been reported [21,27] that the SR (SF2/
ASF, SC35, SRp40 and SRp55) protein family are inhibitors of
CFTR exon 9 alternative splicing via their interaction with the
(TG)m and (T)n loci and the ISS, respectively; Interestingly, the
expression level is higher in most patients with cystic fibrosis.
The genotype of our two patients is, for the first, TG11T7/
TG10T9, and for the second, TG10T9/TG10T9, which induce
less 9 exon skipping. These genotypes, combined with the
increase in the score values of SR proteins, may abolish the
exon 9 skipping.
Our data indicate that the analysis of CFTR mRNA is an
important tool for identifying mutations that cannot be found
through normal procedure for DNA analysis. The detection of
pseudo-exon mutations may be of significant importance in
attempting to carry out a novel therapeutic molecular approach
to modulate the regulation of pseudo-exon inclusion events.
Indeed, the development of pseudo-exon skipping therapies
in CF represents a type of personalized medicine, directed at
individual patients with private mutations. This therapeutic
approach is carried out through the use of small interfering RNA
(siRNA) which binds to the mutation on the DNA regions and
abolishes the production of abnormal RNA in CF patients.Acknowledgments
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